{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:49:11Z","timestamp":1763642951909,"version":"build-2065373602"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"crossref","award":["CMRPG3I0271-2"],"award-info":[{"award-number":["CMRPG3I0271-2"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Abrupt alanine aminotransferase (ALT) elevation during direct-acting antiviral agents (DAA) treatment is an uncommon but noticeable adverse event in chronic hepatitis C (CHC) patients, which may lead to early termination of treatment. This study aims to investigate the incidence, outcome and predictors of the on-treatment ALT elevation during DAA therapy.<\/jats:p>\n                    <jats:p>CHC patients treated with DAA regimen in Chang Gung Memorial Hospital, Linkou branch during March 2015 to March 2019 were recruited. Prospective scheduled ALT assessment at baseline, 2nd, 4th, 8th, and 12th\/24th weeks were recorded. Pretherapy host and viral factors were compared between patients with and without on-treatment ALT elevation. Multivariate logistic regression was used for independent factors for on-treatment ALT elevation.<\/jats:p>\n                    <jats:p>\n                      A total of 1563 CHC patients treated with grazoprevir\/elbasvir, glecaprevir\/pibrentasvir and sofosbuvir-based regimen were analyzed. On-treatment ALT elevation occurred in 10.9% patients while those treated with glecaprevir\/pibrentasvir had the least possibility (5.4%). Only 1.4% patients had \u2265grade 3 ALT elevation events. The presence of such events had no impact on sustained virological response 12 rates. Hepatitis B virus coinfection (aOR: 3.599, P\u200a&lt;\u200a0.001) and higher pretherapy ALT (1-5x, \u22655x upper limit of normal: aOR: 2.632, P\u200a=\u200a0.024, aOR: 4.702,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a.011, respectively) were significant predictors for ALT elevation.\n                    <\/jats:p>\n                    <jats:p>On-treatment ALT elevation occurred in one-tenth CHC patients treated with preferred DAAs but had no impact on sustained virological response rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000021898","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T02:01:21Z","timestamp":1599703281000},"page":"e21898","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Yen-Chun","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch"},{"name":"College of Medicine, Chang Gung University, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-1259","authenticated-orcid":false,"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch"},{"name":"College of Medicine, Chang Gung University, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ting","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch"},{"name":"College of Medicine, Chang Gung University, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Chung","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch"},{"name":"College of Medicine, Chang Gung University, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch"},{"name":"College of Medicine, Chang Gung University, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch"},{"name":"College of Medicine, Chang Gung University, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yen","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch"},{"name":"College of Medicine, Chang Gung University, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch"},{"name":"College of Medicine, Chang Gung University, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Shyan","family":"Sheen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou branch"},{"name":"College of Medicine, Chang Gung University, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"R1-20251104","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J Hepatol"},{"key":"R2-20251104","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Liver","year":"2018","journal-title":"J Hepatol"},{"key":"R3-20251104","first-page":"S31","article-title":"Treatment of chronic hepatitis C in patients with decompensated cirrhosis","volume":"4","author":"Everson","year":"2004","journal-title":"Rev Gastroenterol Dis"},{"key":"R4-20251104","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"R5-20251104","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"R8-20251104","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2013","journal-title":"J Hepatol"},{"key":"R9-20251104","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Eng J Med"},{"key":"R10-20251104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Int Med"},{"key":"R11-20251104","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","article-title":"Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis","volume":"16","author":"Asselah","year":"2018","journal-title":"Clin Gastroentero Hepatol"},{"key":"R12-20251104","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","article-title":"High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1-6 patients without cirrhosis","volume":"69","author":"Puoti","year":"2018","journal-title":"J Hepatol"},{"key":"R13-20251104","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"Pawlotsky","year":"2015","journal-title":"J hepatol"},{"key":"R14-20251104","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"R15-20251104","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","volume":"67","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R18-20251104","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443344","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"9","year":"2016","journal-title":"Obesity facts"},{"key":"R19-20251104","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"R20-20251104","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/1060028015570729","article-title":"Ombitasvir\/paritaprevir\/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection","volume":"49","author":"Klibanov","year":"2015","journal-title":"Ann Pharmacotherapy"},{"key":"R21-20251104","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","article-title":"Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial","volume":"17","author":"Forns","year":"2017","journal-title":"Lancet"},{"key":"R22-20251104","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir\u2013pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Eng J Med"},{"key":"R23-20251104","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","article-title":"Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b\u2013infected Japanese patients with or without cirrhosis","volume":"62","author":"Kumada","year":"2015","journal-title":"Hepatology"},{"key":"R24-20251104","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","article-title":"Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection","volume":"149","author":"Gane","year":"2015","journal-title":"Gastroenterology"},{"key":"R25-20251104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jhep.2015.08.015","article-title":"Efficacy and safety of ombitasvir\/paritaprevir\/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I\/II trials","volume":"64","author":"Dore","year":"2016","journal-title":"J hepatol"},{"key":"R26-20251104","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.13265","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment","volume":"27","author":"Liu","year":"2020","journal-title":"J Viral Hepat"},{"key":"R27-20251104","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/jmv.24360","article-title":"Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"88","author":"Akuta","year":"2016","journal-title":"J Med Virol"},{"key":"R28-20251104","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/j.gastro.2017.11.011","article-title":"Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV","volume":"154","author":"Liu","year":"2018","journal-title":"Gastroenterology"},{"key":"R29-20251104","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1093\/cid\/civ474","article-title":"Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir","volume":"61","author":"Collins","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R30-20251104","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"Mucke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R31-20251104","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:00:27Z","timestamp":1762243227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":27,"journal-issue":{"issue":"37","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021898","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"2020-04-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}